Based on the vTv Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for vTv Therapeutics Inc is USD 35.00 over the next 12 months. vTv Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of vTv Therapeutics Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, vTv Therapeutics Inc’s stock price was USD 18.53. vTv Therapeutics Inc’s stock price has changed by +5.89% over the past week, +20.40% over the past month and -25.88% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for vTv Therapeutics Inc
No recent average analyst rating found for vTv Therapeutics Inc
Company Overview vTv Therapeutics Inc
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC. Read Less
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-se...Read More
Frequently Asked Questions About vTv Therapeutics Inc (VTVT) Stock
Based on ratings from 1 analysts vTv Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on VTVT's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for VTVT is USD 35.00 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 35.
Unfortunately we do not have enough data on VTVT's stock to indicate if its overvalued.
The last closing price of VTVT's stock was USD 18.53.
The most recent market capitalization for VTVT is USD 0.05B.
Based on targets from 1 analysts, the average taret price for VTVT is projected at USD 35.00 over the next 12 months.
This means that VTVT's stock price may go up by +88.88% over the next 12 months.
We can't find any ETFs which contains vTv Therapeutics Inc's stock.
As per our most recent records vTv Therapeutics Inc has 16 Employees.
vTv Therapeutics Inc's registered address is 3980 Premier Drive, High Point, NC, United States, 27265.
You can get more information about it from vTv Therapeutics Inc's website at https://vtvtherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About vTv Therapeutics Inc (VTVT) Stock
Based on ratings from 1 analysts vTv Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on VTVT's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for VTVT is USD 35.00 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 35.
Unfortunately we do not have enough data on VTVT's stock to indicate if its overvalued.
The last closing price of VTVT's stock was USD 18.53.
The most recent market capitalization for VTVT is USD 0.05B.
Based on targets from 1 analysts, the average taret price for VTVT is projected at USD 35.00 over the next 12 months.
This means that VTVT's stock price may go up by +88.88% over the next 12 months.
We can't find any ETFs which contains vTv Therapeutics Inc's stock.
As per our most recent records vTv Therapeutics Inc has 16 Employees.
vTv Therapeutics Inc's registered address is 3980 Premier Drive, High Point, NC, United States, 27265.
You can get more information about it from vTv Therapeutics Inc's website at https://vtvtherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VTVT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
